Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29693646 | 0.87 | NPC1 (0.55) | NPC1ALDH1A1HTTEGFRSMN1; SMN2 | |
| SCHEMBL29948971 | 0.87 | NPC1 (0.55) | NPC1ALDH1A1HTTEGFRSMN1; SMN2 | |
| SCHEMBL1923392 | 0.87 | NPC1 (0.55) | NPC1ALDH1A1HTTEGFRSMN1; SMN2 | |
| SCHEMBL29948741 | 0.87 | NPC1 (0.55) | NPC1ALDH1A1HTTEGFRSMN1; SMN2 | |
| SCHEMBL445410 | 0.79 | KMT2A (0.44) | ALDH1A1KMT2AMEN1L3MBTL1LMNA | |
| SCHEMBL30435397 | 0.79 | KMT2A (0.44) | ALDH1A1KMT2AMEN1L3MBTL1LMNA | |
| SCHEMBL14459586 | 0.79 | NPC1 (0.47) | NPC1ALDH1A1HTTEGFRSMN1; SMN2 | |
| SCHEMBL8299614 | 0.75 | ALDH1A1 (0.46) | NPC1ALDH1A1HTTEGFRSMN1; SMN2 | |
| SCHEMBL1345232 | 0.75 | GAA (0.42) | ALDH1A1SMN1; SMN2TSHRHPGD | |
| SCHEMBL6714580 | 0.74 | KMT2A (0.40) | ALDH1A1KMT2AMEN1L3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116925076-A | Nevirapine intermediate compound and preparation method and application thereof | 山东新时代药业有限公司 | 2023-10-24 | — | — | CN | disclosed |
| CN-116813538-A | Nevirapine intermediate compound and preparation method thereof | 山东新时代药业有限公司 | 2023-09-29 | — | — | CN | disclosed |
| CN-116410129-A | Nevirapine intermediate compound | 山东新时代药业有限公司 | 2023-07-11 | — | — | CN | disclosed |
| US-20040023290-A1 | Novel therapeutic agents that modulate enzymatic processes | THERAVANCE BIOPHARMA R&D IP, LLC | 2004-02-05 | — | — | US | disclosed |
| EP-0989857-A4 | NOVEL THERAPEUTIC AGENTS THAT MODULATE ENZYMATIC PROCESSES | ADVANCED MEDICINE INC (US) | 2001-01-17 | — | — | EP | disclosed |
| WO-1999064048-A9 | INHIBITORS OF HIV REVERSE TRANSCRIPTASE | ADVANCED MEDICINE INC (US) | 2000-07-20 | — | — | WO | disclosed |
| EP-1003541-A1 | INHIBITORS OF HIV REVERSE TRANSCRIPTASE | Advanced Medicine, Inc. (US) | 2000-05-31 | — | — | EP | disclosed |
| EP-0989857-A1 | NOVEL THERAPEUTIC AGENTS THAT MODULATE ENZYMATIC PROCESSES | Advanced Medicine, Inc. (US) | 2000-04-05 | — | — | EP | disclosed |
| WO-1999064037-A1 | NOVEL THERAPEUTIC AGENTS THAT MODULATE ENZYMATIC PROCESSES | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
| WO-1999064048-A1 | INHIBITORS OF HIV REVERSE TRANSCRIPTASE | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
| US-5532358-A | Method for preparing alkyl-5,11-dihydro-6h-dipyrido[3,2-B:2',3'-E] [1,4] diazepin-6-ones | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 1996-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023290-A1 | Novel therapeutic agents that modulate enzymatic processes | RNASE1, ENGASE, ENTPD5 | NPC1 3927/4885ALDH1A1 1021/4885HTT 4327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.